S&P 500 Industrials Sector SEC Filings — April 28, 2026

28-04-2026

On April 22, 2026, Littelfuse, Inc. held its 2026 Annual Meeting of Stockholders, where all eight director nominees were elected with overwhelming support (For votes ranging from 21.3M to 23.0M shares). Stockholders also approved, on an advisory basis, the compensation of named executive officers (21.2M For vs. 1.8M Against) and ratified Deloitte & Touche LLP as independent auditors for fiscal year ending December 26, 2026 (23.8M For). Additionally, the Board approved updated forms of restricted stock unit and performance share award agreements under the company's long-term incentive plans, incorporating death or disability as qualifying for retirement vesting.

• ·All director elections had 785,230 broker non-votes.
• ·Annual Meeting held April 22, 2026; fiscal year ends December 26, 2026.
• ·New award agreements filed as Exhibits 10.1 (RSU under Littelfuse Plan), 10.2 (PSU under Littelfuse Plan), 10.3 (RSU under LF/IXYS Plan).

28-04-2026

Coronado Global Resources Inc. reported Q1 March 2026 results with ROM production declining 21.7% QoQ to 5.4 Mt from 6.9 Mt and saleable production down 30.7% QoQ to 3.0 Mt, reflecting planned maintenance, CHPP shutdown at Curragh, longwall moves at Buchanan, weather delays, and Logan idling due to weak High-Vol market. Sales volumes fell 23.2% QoQ to 3.5 Mt, but realised met coal pricing rose 11.2% QoQ to US$165.4/t and overall group pricing increased 9.1% to US$133.2/t; Buchanan doubled EBITDA to US$30M despite challenges, and US$26M was received under revised Stanwell arrangements. Average mining cash costs surged 40.6% QoQ to US$135.3/t due to lower volumes, though expected to improve with higher run-rates.

• ·Logan Complex idled following WARN Act notice due to constrained High-Vol market demand.
• ·Curragh Complex experienced temporary coal recovery constraints from rain after strong overburden removal.
• ·Export sales increased to 74.4% of total group volumes QoQ (+1.2%).
• ·PLV HCC FOB AUS Index averaged US$234.7/t in Mar Q26 (+17.3% QoQ).

28-04-2026

Ligand Pharmaceuticals announced a definitive agreement dated April 27, 2026, to acquire XOMA Royalty Corporation for $39 per share in cash plus a CVR tied to Janssen Biotech Tremfya litigation proceeds, expected to close in Q3 2026 and immediately accretive by $0.50 to adjusted core EPS in 2026 and $1.50 in 2027. The deal adds seven commercial royalties (Vabysmo, Ojemda, Miplyffa as key drivers) and over 100 development-stage programs, more than doubling Ligand's portfolio, prompting raised 2026 guidance to royalty revenue of $225-250 million (from $200-225 million), total revenue $270-310 million (from $245-285 million), and adjusted core EPS $8.50-9.50 (from $8-9). No declines or flat metrics were reported, positioning Ligand for compounded growth.

• ·XOMA portfolio includes royalties, tax, and IP assets built since 2017 pivot, with nine acquisitions in last two years.
• ·Funding via cash on hand and credit facility, retaining capacity for $150-250M annual royalty asset investments.
• ·Additional catalysts: Ojemda Japan marketing decision, Miplyffa Europe marketing decision in 2026.
• ·Filspari FDA approval for FSGS (rare kidney disease) expands beyond IgAN; Ligand 9% royalty.

28-04-2026

Genprex, Inc. announced via press release that its research collaborators will present positive preclinical data on the Pdx1/MafA gene therapy (PM or GPX-002) at the 2026 ASGCT Annual Meeting (May 11-15, 2026, Boston), demonstrating reversal of hyperglycemia in Type 2 diabetic mouse models via intrapancreatic AAV delivery. Key results at four weeks post-treatment include improved ex-vivo glucose-stimulated insulin secretion (GSIS) comparable to healthy controls, enhanced β-cell function and maturation, increased mature insulin granules, and a transcriptomic shift toward β-cell maturity. The data supports technical translatability to humans using endoscopic retrograde cholangiopancreatography for potential long-term T2D glycemic control.

• ·Study used eight-week-old male C57BL/6 mice on high fat diet (HFD) for 24 weeks or regular diet (RD).
• ·Treatments: intrapancreatic infusion of AAV-8 PM (global-islet or β-cell specific) vs. control virus.
• ·Assessments: intraperitoneal glucose/insulin tolerance testing, HOMA-IR, glucagon secretion, pancreatic histology, β-/α-cell mass, electron microscopy, ex-vivo GSIS, single-cell RNA sequencing.
• ·Electron microscopy: PM treatment increased total/mature insulin granules, decreased immature granules in HFD mice.
• ·Abstract title: 'Pancreatic Delivery of AAV-Pdx1/MafA Reverses Hyperglycemia in a Preclinical Model of Type 2 Diabetes.'

28-04-2026

Shutterstock reported Q1 2026 revenue of $199.2 million, down 18% YoY from $242.6 million, driven by a 12% decline in Content revenue to $178.1 million and a 47% drop in Data, Distribution, and Services to $21.0 million, resulting in a net loss of $47.6 million versus prior year income of $18.7 million. Adjusted EBITDA fell 33% to $42.7 million amid operational discipline and investments in AI services, while subscribers decreased to 993,000 from 1,079,000 and paid downloads dropped to 104.1 million from 120.9 million. The company provided an update on its pending merger with Getty Images, noting DOJ clearance but ongoing CMA concerns over UK editorial content, potentially requiring divestiture of Rex Features, Backgrid, and Splash News businesses that generated $32.7 million in 2025 revenue.

• ·DOJ HSR waiting period expired February 23, 2026 without conditions.
• ·CMA statutory deadline for final merger report: June 14, 2026.
• ·2025 UK Editorial revenue: $10.6 million.
• ·Q1 2026 dividend: $0.36 per share, next payable June 18, 2026 to record June 4, 2026.
• ·Adjusted free cash flow Q1 2026: $13.1 million, down from prior year.

28-04-2026

Axogen reported first quarter 2026 revenue of $61.5 million, up 26.6% YoY from $48.6 million, driven by double-digit growth across all target markets including Extremities, Oral Maxillofacial & Head and Neck, and Breast, with gross margin expanding to 75.2% from 71.9%. However, net loss widened significantly to $19.6 million ($0.38 per share) from $3.8 million ($0.08 per share), primarily due to a $16.8 million loss on debt extinguishment following repayment using proceeds from a January public offering. The company raised full-year 2026 revenue guidance to at least 20% growth or $270 million, with gross margin of 74-76% and free cash flow positivity expected.

• ·Received positive coverage decisions from Cigna and Elevance Health.
• ·Effective January 1, 2026, CMS created new Level 3 Nerve Procedure Code, increasing Avance facility reimbursement 40% YoY to $8,965 (hospital outpatient) and 35% to $6,157 (ASC-based).
• ·Closed upsized public offering on January 23, 2026, with sale of 4.6 million shares yielding $133.3 million net proceeds; $69.7 million used to fully repay and terminate Oberland loan facility.
• ·Double-digit revenue growth in all markets: Extremities, Oral Maxillofacial & Head and Neck, Breast.

28-04-2026

Cabaletta Bio, Inc.'s DEF 14A proxy statement outlines six proposals for the annual meeting: election of Class I directors Scott Brun, M.D. and Shawn Tomasello, MBA; ratification of Ernst & Young LLP as independent auditors for fiscal year ending December 31, 2026; approval of Amendment No. 2 to the 2019 Stock Option and Incentive Plan; amendment to certificate of incorporation to increase authorized common stock from 300,000,000 to 600,000,000 shares; non-binding advisory approval of named executive officer compensation; and approval to adjourn the meeting if needed for additional solicitation. The board has six members serving staggered three-year terms, with no financial performance data or period comparisons provided. Director bios highlight extensive biopharma experience, including past roles in major acquisitions like Kite Pharma ($11.9B) and Pharmacyclics ($21.0B).

• ·Board removal requires affirmative vote of at least 75% of outstanding shares entitled to vote.
• ·Vacancies on board filled by majority vote of directors then in office.
• ·Annual meeting voting results to be filed via Form 8-K within four business days, with preliminary if needed.
• ·Nominating committee emphasizes diversity in expertise, experience, background, and gender for director candidates.

28-04-2026

Controladora Vuela Compania de Aviacion, S.A.B. de C.V. (Volaris) discloses 100% equity ownership in five Mexican trusts (Banco Multiva Fidecomisos CIB/3853, 3855, 3866, 3867, 3921) for financing pre-delivery payments under its Airbus aircraft purchase agreement, with Banco Multiva assuming rights from CIBanco effective September 2, 2025. The company also reports 100% ownership in Fidecomiso CIB/3249, through which subsidiary Volaris Opco issued three series of asset-backed securities notes (15 million units each): VOLARCB 19 (Ps.1.5B or $78.5M, fully amortized June 20, 2024), VOLARCB 21L (Ps.1.5B or $72.1M), and VOLARCB 23 (Ps.1.5B or $85.8M), under CNBV-approved programs up to Ps.3.0B ($157.1M/$144.2M) and Ps.5.0B ($286.2M). Two additional 100%-owned administrative trusts (F/745291 and CIB/3081) manage shares.

• ·VOLARCB 19 notes fully amortized on June 20, 2024.
• ·Banco Multiva assumed all rights and obligations of CIBanco effective September 2, 2025.

28-04-2026

Innovative Digital Investors Acquisition Corp., a blank check company focused on financial services targets in North America, has filed Amendment No. 5 to its S-1 registration statement for an IPO of 20,000,000 units priced at $10.00 each, consisting of one share of common stock and one-half of one redeemable warrant exercisable at $11.50. The sponsor commits to purchasing 275,000 private units at $10.00 and 1,000,000 Sponsor OTM warrants at $0.10 each (exercisable at $15.00), for total consideration of $2,850,000, while initial stockholders hold 7,475,000 founder shares purchased for approximately $43,333. The company has 24 months to complete an initial business combination, with standard SPAC risks including potential high redemptions leading to significant dilution (e.g., NTBV as low as $0.15 at maximum redemption).

• ·Underwriters have a 45-day option to purchase up to 3,000,000 additional units for over-allotments.
• ·Warrants become exercisable on the later of 30 days after initial business combination or 12 months from IPO closing, expiring 5 years post-combination (10 years for Sponsor OTM Warrants).
• ·Pro forma NTBV per share ranges from $7.48 (no redemption) to $0.15 (maximum redemption assuming full over-allotment).
• ·Public stockholders can redeem up to 15% of shares upon business combination at trust account value per share.
• ·Company is an emerging growth company under federal securities laws.
• ·Nasdaq listing applied for: units IDIAU, common stock IDIA, warrants IDIAW.
• ·Sponsor reimbursed $15,000 per month for office space and services.

28-04-2026

Baker Boyer National Bank filed its 13F-HR on April 28, 2026, disclosing total holdings of $332827952 across 119 positions as of March 31, 2026. The portfolio emphasizes ETFs, with the largest positions in DFA U.S. Core Equity 2 ETF ($63332590), DFA World Ex-U.S. Core Equity 2 ETF ($56925839), and Vanguard Muni Bond Tax Exempt ($56226828). Notable individual stock holdings include Microsoft Corp ($7074319), Apple Inc ($4349199 sole), and Paccar Inc ($4216443).

• ·Portfolio includes both sole discretionary (SH SOLE) and defined (SH DFND) holdings.
• ·Filer located in Walla Walla, WA; CIK 0001079398.
• ·No other managers reported (0 managers).

28-04-2026

Ryan Investment Management, Inc. filed a 13F-HR report on April 28, 2026, disclosing its equity holdings as of March 31, 2026, with a total portfolio value of $177829558 across 20 positions, primarily ETFs. Top holdings include iShares MSCI EAFE ETF at $36297870, ProShares Short QQQ ETF at $34302469, ProShares Short S&P500 ETF at $34034020, iShares Russell 1000 Value ETF at $24115865, and State Street SPDR Bloomberg 1-3 Month T-Bill ETF at $11541600. The portfolio features a mix of long equity ETFs, short ETFs, bond ETFs, and one individual stock position in Eli Lilly & Co. valued at $836071.

• ·Filing filed as of April 28, 2026, for period ended March 31, 2026.
• ·All positions reported with sole voting power.
• ·Business address: 22860 Two Rivers Road, Suite 200, Basalt, CO 81621.

28-04-2026

Patriot National Bancorp, Inc. entered into indemnification agreements on April 27, 2026, with directors Anahit Magzanyan, Jonathan Roth, Mario De Tomasi, Carlos P. Salas, and Jeffrey Seabold, providing indemnity for expenses related to their service and advancement of expenses. On April 24, 2026, effective April 26, 2026, the company executed addenda to employment agreements with executives Steven A. Sugarman (President and Bank CEO), Carlos P. Salas (CFO), Angie Miranda (Chief Risk Officer), and William Paul Simmons (Chief Credit Officer), adding severance provisions including cash multiples of compensation, pro rata bonuses, continued health benefits, accelerated equity vesting, and limits on excise taxes under IRC Sections 280G and 4999. These actions were approved by the Compensation Committee and Board of Directors.

• ·Indemnification agreements reference standard form filed as Exhibit 10.1 on December 31, 2024.
• ·Addenda attached as Exhibits 10.1 to 10.4.

28-04-2026

The Real Brokerage Inc. announced an agreement to acquire RE/MAX Holdings, Inc., one of the world’s leading franchisors of real estate services, scaling Real's agent network from 33,000 in North America to over 180,000 agents across more than 120 countries and territories upon closing. This combination aims to enhance Real's technology platform with RE/MAX's iconic brand and global franchisee network, described as a 5x larger audience. The transaction is expected to close in the second half of 2026, subject to regulatory approvals, shareholder votes, and other closing conditions, with standard M&A risks including integration challenges and potential disruptions noted.

• ·Real founded 12 years ago (2014).
• ·Company-wide town hall scheduled for 2 PM EST on April 28, 2026.
• ·Operations to continue separately until closing; no immediate day-to-day changes for Real employees.

28-04-2026

Oversea-Chinese Banking Corp Ltd filed its 13F-HR on April 28, 2026, disclosing US equity holdings as of March 31, 2026, across five managed entities including Bank of Singapore Limited and Great Eastern Life Assurance Company Limited. Key positions include Apple Inc (market value 85421362 DFND 3), Amazon.com Inc (73620032 DFND 3), Broadcom Inc (62090091 DFND 3), Alphabet Inc CAP STK CL A (68725934 DFND 3), and Citigroup Inc (52301063 DFND 1), with additional derivatives like puts on Advanced Micro Devices Inc and calls. No prior period data is provided for comparisons, reflecting a routine quarterly snapshot of significant US market exposure.

• ·Filing covers 5 managed accounts (CIK managers: 028-23120, 028-22959, 028-22904, 028-22827, 028-24129)
• ·Signed in Singapore on April 28, 2026
• ·Includes derivative positions such as puts on Adobe Inc, Alphabet Inc, Amazon.com Inc, and Advanced Micro Devices Inc

28-04-2026

UPS reported Q1 2026 consolidated revenues of $21.2B with operating profit of $1.27B (6.0% margin) and adjusted operating profit of $1.32B (6.2% margin), diluted EPS of $1.02 and adjusted EPS of $1.07. While International segment revenue grew 3.8% to $4,540M, U.S. Domestic revenue declined 2.3% to $14,125M and Supply Chain Solutions revenue fell 6.5% to $2,537M; operating profits declined in U.S. Domestic to $515M (from $979M) and International to $547M (from $641M), though Supply Chain Solutions improved to $205M (from $46M). The company reaffirms FY2026 guidance of approximately $89.7B revenue, 9.6% adjusted operating margin, $3.0B capex, and $5.4B dividends.

• ·GAAP diluted EPS of $1.02; non-GAAP adjusted diluted EPS of $1.07 for Q1 2026, including after-tax transformation charges of $42M ($0.05 per share).
• ·Achieved $600M program cost savings in Q1 2026 from Network Reconfiguration and Efficiency Reimagined; expect $3B full-year savings.
• ·Program costs incurred to date $599M as of March 31, 2026, including $55M in Q1 2026; expected non-GAAP adjusted operating expense exclusion of $1.3B-$1.5B in 2026.
• ·Initiatives expected to conclude by 2027.

28-04-2026

Flutter Entertainment plc announced updates to its Board Committee Memberships, effective from the conclusion of the Annual General Meeting on May 29, 2026. Sally Susman will be appointed to the Risk and Sustainability Committee, and David Kenny to the Compensation and Human Resources Committee.

• ·Filing date: April 28, 2026
• ·Enquiries: Edward Traynor, +353872232455

28-04-2026

ArcBest reported first quarter 2026 revenue of $998.8 million, up from $967.1 million in Q1 2025, with Asset-Based revenue increasing to $655.0 million (+2.2% per day) driven by 6.5% higher tonnage per day and Asset-Light revenue rising to $377.7 million (+7.0% per day) on 9.8% more shipments per day. However, the company swung to a net loss of $1.0 million ($-0.05 per diluted share) from net income of $3.1 million ($0.13 per diluted share), Asset-Based operating income fell to $17.5 million with operating ratio worsening to 97.3% from 95.9%, and non-GAAP net income declined to $7.2 million from $11.9 million. The company returned more than $10 million to shareholders through balanced capital allocation.

• ·Conference call scheduled for April 28, 2026 at 9:30 a.m. ET.
• ·Customer contract renewals and deferred pricing agreements averaged 6.3% increase in Q1 2026.
• ·Total assets as of March 31, 2026: $2,458.4 million, up slightly from $2,452.7 million at Dec 31, 2025.
• ·14,000 employees across 250 campuses and service centers.

28-04-2026

Hilton reported strong Q1 2026 financial results, including net income of $383 million (up 27.7% YoY from $300 million), Adjusted EBITDA of $901 million (up 13.3% YoY from $795 million), and system-wide comparable RevPAR growth of 3.6% YoY driven by gains in occupancy and ADR. The company added 16,300 rooms (net 10,900), grew its development pipeline 5% YoY to 527,000 rooms, and returned $860 million to shareholders via repurchases and dividends. However, Middle East & Africa occupancy declined 4.1 percentage points YoY, and full-year RevPAR outlook is modest at 2.0-3.0% growth amid anticipated lower Middle East RevPAR.

• ·Total revenues $2,937M in Q1 2026 vs $2,695M in Q1 2025.
• ·Franchise and licensing fees $696M in Q1 2026 (+11.4% YoY).
• ·Debt weighted average interest rate 5.00% with no material maturities before April 2027.
• ·Q2 2026 Adjusted EBITDA projected $1,015M-$1,035M.
• ·Portfolio spans 27 brands in 144 countries and territories.

28-04-2026

China Universal Asset Management Co., Ltd. filed its 13F-HR report as of March 31, 2026, disclosing 502 equity holdings with a total market value of $1,320,814,008, all held with sole voting authority. Top positions include NVIDIA Corp ($80,937,655, 464,069 shares), Apple Inc ($61,972,473, 244,188 shares), Microsoft Corp ($49,646,830, 134,119 shares), Alphabet Inc-CL A ($48,822,224, 169,781 shares), and Amazon.com Inc ($42,299,637, 203,100 shares). No period-over-period changes or performance metrics are provided in the filing.

• ·All 502 holdings reported as sole ownership with zero shared discretion or other voting authority.
• ·Filing covers period ended March 31, 2026, submitted April 28, 2026.

28-04-2026

SBI Okasan Asset Management Co. Ltd. filed its 13F-HR report on April 28, 2026, disclosing U.S. equity holdings as of March 31, 2026, totaling $2,440,283,124 across 321 positions, all with sole voting power. The portfolio features significant concentrations in technology stocks, including NVIDIA Corp valued at $14,568,324 (88,202 shares), Alphabet Inc Cl A at $11,751,748 (42,968 shares), and Microsoft Corp at $8,360,896 (23,292 shares). No prior period data is provided in the filing for comparison.

• ·Report period end date: March 31, 2026
• ·Filed as of date: April 28, 2026
• ·Date as of change: April 27, 2026
• ·All positions reported with sole voting power (SH SOLE)

28-04-2026

Alpha Tau Medical Ltd. filed a Form F-3 shelf registration statement on April 28, 2026, to register up to $300,000,000 of ordinary shares, warrants, debt securities, subscription rights, and/or units. It includes an at-the-market (ATM) offering of up to $100,000,000 in ordinary shares through H.C. Wainwright & Co., LLC as sales agent, replacing a prior agreement with Jefferies LLC terminated on April 27, 2026. The filing incorporates by reference the company's Annual Report on Form 20-F for the year ended December 31, 2025, audited by Kost Forer Gabbay & Kasierer (EY Global), and notes challenges in enforcing U.S. judgments against the Israeli company.

• ·Sales Agreement dated April 27, 2026, with H.C. Wainwright & Co., LLC for ATM sales on Nasdaq Capital Market or other methods.
• ·Prior Open Market Sale Agreement with Jefferies LLC dated April 3, 2023, terminated April 27, 2026.
• ·Fiscal year end: December 31; Annual Report on Form 20-F filed March 9, 2026.
• ·Agent for service of process: Alpha Tau Medical, Inc., 1 Union Street, 3rd Floor, Lawrence, MA 01840.

28-04-2026

AvalonBay Communities reported Q1 2026 EPS of $2.33, up 40.4% YoY from $1.66, primarily due to real estate gains, while FFO per share declined 2.2% to $2.72 and Core FFO per share remained flat at $2.83 versus prior year. Same Store Residential revenue increased 1.6% to $703,976,000, but operating expenses rose 4.7% to $224,039,000, limiting NOI growth to 0.2% at $479,937,000. The company completed one development (Avalon Lake Norman for $102,000,000), started two more totaling $188,000,000 estimated cost, sold three communities for $340,750,000, repurchased $198,480,000 in stock, and issued Q2 2026 guidance while reaffirming full-year Core FFO outlook but lowering EPS expectations.

• ·25 wholly-owned development communities under construction with 8,673 apartment homes and 69,000 square feet of commercial space for estimated $3,390,000,000 total capital cost.
• ·Received $17,580,000 repayment on one SIP mezzanine loan; new $15,000,000 commitment in April 2026, both for Metro NY/NJ multifamily projects.
• ·Annualized Net Debt-to-Core EBITDAre of 4.8 times; Unencumbered NOI of 95% for Q1 2026.
• ·$914,354,000 remaining capacity under 2026 Stock Repurchase Program.
• ·Q2 2026 guidance: EPS $1.23-$1.33, FFO per share $2.68-$2.78, Core FFO per share $2.72-$2.82; full-year Core FFO reaffirmed, EPS outlook $5.92-$6.42.
• ·Conference call on April 28, 2026 at 1:00 PM ET.

28-04-2026

Avery Dennison reported first quarter 2026 net sales of $2,298.5 million, up 7.0% YoY, driven by 11.4% growth in Materials Group to $1,649.3 million, though Solutions Group sales declined 2.8% to $649.2 million and organic sales grew only 1.1%. Adjusted EPS increased 7.4% to $2.47, with adjusted free cash flow of $104.4 million, while the company returned $133 million to shareholders via dividends and repurchases. Second quarter 2026 adjusted EPS guidance is $2.43 to $2.53.

• ·Net debt to adjusted EBITDA ratio of 2.4x at Q1 2026 end.
• ·Adjusted operating margin for Materials Group 15.4% (down 20 bps YoY); for Solutions Group 9.0% (down 120 bps YoY).
• ·Q1 2026 adjusted tax rate of 26.2%.
• ·Q1 2026 pre-tax restructuring charges of $16 million.

28-04-2026

For Q1 FY2026, Meridian Holdings Inc. (a subsidiary of Golden Matrix Group, Inc.) reported revenues of $50,103,870, up 17% YoY from $42,723,053, with gross profit rising 16% to $28,144,240 and achieving operating income of $3,157,124 versus a prior-year loss of $106,017, alongside net income of $2,168,157 compared to a $258,217 loss. However, total assets declined 5% QoQ to $111,867,270 from $118,078,800, cash and equivalents fell 10% to $16,234,441, and net cash from operations decreased 33% YoY to $5,155,437 from $7,739,637.

• ·Accounts receivable, net decreased QoQ to $5,498,687 from $7,954,116.
• ·Selling, general and administrative expenses increased slightly 3% YoY to $24,987,116.
• ·Foreign exchange loss of $412,194 in Q1 2026 versus gain of $433,668 in Q1 2025.
• ·Cash used in investing activities $2,468,595 in Q1 2026, down from $5,340,839 YoY.
• ·Debt repayments of $3,791,674 in Q1 2026.

28-04-2026

Ocugen, Inc. (OCGN) filed a DEFA14A Definitive Additional Proxy Materials on April 28, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive proposals, financial data, or other details are provided in the filing header.

28-04-2026

reAlpha Tech Corp. reported Q1 2026 revenue of $841,062, down 9.1% YoY from $925,635, while gross profit increased 6.5% YoY to $552,265. However, operating expenses surged 64.3% YoY to $4,832,923, resulting in an operating loss of $4,280,658, up 76.7% from $2,422,258, and net loss widened to $4,338,495 from $2,850,167 YoY. Total assets declined 18.8% QoQ to $17,637,105 from $21,717,331, with cash dropping 40.1% to $4,667,612, and stockholders' equity fell 28.3% to $8,253,734.

• ·Net cash used in operating activities increased to $3,123,752 in Q1 2026 from $2,267,103 in Q1 2025.
• ·Derivative liability stood at $4,602,480 as of March 31, 2026.
• ·Intangible assets, net: $4,164,833 as of March 31, 2026 (down from $4,306,553).
• ·Goodwill: $7,459,125 unchanged QoQ.
• ·Basic and diluted loss per share: $(0.03) in Q1 2026 vs $(0.06) in Q1 2025.

28-04-2026

Apellis Pharmaceuticals, Inc. filed a 10-K/A amendment disclosing a 11.7% YoY increase in total auditor fees to $2,339,491 in 2025 from $2,093,952 in 2024, driven by higher audit fees (+9.7%). Executive compensation performance scorecard showed mixed results, with U.S. revenue goals (40% weighting) only partially achieved while several pipeline advancements exceeded targets. Equity compensation plans as of December 31, 2025, include 15,530,536 securities outstanding upon exercise at a weighted average price of $17.60, with 4,106,250 shares available for future issuance.

• ·2026 Annual Cash Incentive Plan elements: 50% weighted on FDA SYFOVRE prefilled syringe approval by Dec 31, 2026; 50% on cumulative U.S. EMPAVELI revenue Jul 1-Dec 31, 2026.
• ·Performance scorecard: Regulatory and Pipeline (40%) mostly exceeded; Revenue (40%) partially achieved; Operational Effectiveness (20%) mixed with some exceeded and partially achieved.
• ·Approved equity plans weighted average exercise price $17.20; non-approved $27.58.

28-04-2026

Passage Bio, Inc. announced a Restructuring Plan on April 28, 2026, reducing its workforce by approximately 75% to decrease operating expenses as part of reviewing strategic alternatives to maximize shareholder value. The plan is expected to incur approximately $3.3 million in aggregate severance and exit costs, primarily in Q2 2026, with implementation substantially complete in Q2 and Q3 2026. While aimed at cost reduction, the restructuring involves significant upfront costs and uncertainties, with actual results potentially differing materially.

• ·Severance benefits contingent on execution and non-revocation of severance agreement including general release of claims.
• ·Costs subject to assumptions; actual results may differ materially; additional costs possible from strategic alternatives review.

28-04-2026

S&P Global reported first-quarter 2026 revenue of $4.171 billion, up 10% YoY driven by Ratings, Indices, and Market Intelligence, with GAAP net income up 28% to $1.395 billion and adjusted diluted EPS up 14% to $4.97. GAAP operating margin expanded 620 basis points to 48.0% and adjusted operating margin rose 100 basis points to 51.8%, while subscription revenue grew 6% YoY. The company repurchased $1 billion in shares, remains on track for Mobility division separation and a geoscience divestiture, but updated 2026 guidance with reported revenue growth narrowed to 6.3%-8.3% (30 bps lower due to FX) and interest expense $10 million higher.

• ·2026 reported revenue growth guidance: 6.3% to 8.3%; organic constant currency: 6.0% to 8.0%.
• ·2026 adjusted diluted EPS guidance: $19.40 to $19.65.
• ·Mobility Global Investor Day: May 12, 2026.
• ·Geoscience divestiture expected to close H2 2026 or early 2027.
• ·Quarterly cash dividend: $0.97 per share.
• ·Conference call: April 28, 2026 at 8:30 a.m. EDT.

28-04-2026

GuardCap Asset Management Ltd filed its 13F-HR on April 28, 2026, reporting total holdings of $1,746,392,605 as of March 31, 2026, across 27 positions. Key holdings include Accenture PLC Ireland Shs Class A (681,159 shares valued at $88,338,717), Adobe Inc Com (901,517 shares at $26,367,810), and Microsoft Corp Com (1,146,638 shares at $82,306,565). No period-over-period changes are disclosed in the filing.

• ·Filing CIK: 0001732008
• ·SEC File Number: 028-18654
• ·Filer address: 6th Floor, 11 Charles II Street, St. James's, London X0 SW1Y 4NS
• ·Period end date: 2026-03-31

28-04-2026

Rocket Pharmaceuticals, Inc. announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in non-dilutive capital, following FDA accelerated approval of KRESLADI™. Proceeds will support the company's cardiovascular gene therapy pipeline, including clinical-stage programs in Danon disease, PKP2-ACM, and BAG3-DCM, with all programs on track. Pro forma for this transaction, the cash runway extends into the second quarter of 2028.

• ·PRV program reauthorized by U.S. government in February 2026.
• ·Rocket's platform supported by proprietary AAV manufacturing, multi-year cardiac gene therapy data, and experience treating cardiac patients.

28-04-2026

GM Financial reported first quarter 2026 net income of $514 million, up 3% YoY from $499 million and 12% QoQ from $460 million. However, total originations declined 15% YoY to $12.3 billion, with retail loan originations down 14% to $8.3 billion and operating lease originations down 19% to $4.0 billion; delinquencies also rose with 31-60 days at 2.4% (vs 2.2% YoY) and over 60 days at 0.9% (vs 0.7% YoY). Earning assets totaled $123.9 billion at quarter-end, supported by available liquidity of $35.0 billion.

• ·Allowance for loan losses as % of retail finance receivables: 3.6% at Mar 31, 2026 (up from 3.5% at Dec 31, 2025)
• ·Commercial finance receivables: $15.7B at Mar 31, 2026 (down from $16.9B at Mar 31, 2025)
• ·Revenue: $4,276M in Q1 2026 (up from $4,164M in Q1 2025)
• ·Provision for loan losses: $267M in Q1 2026 (down from $328M in Q1 2025)

28-04-2026

General Motors reported first-quarter 2026 revenue of $43.6 billion, down 0.9% YoY from $44.0 billion, and net income attributable to stockholders of $2.6 billion, down 5.7% YoY from $2.8 billion. However, EBIT-adjusted increased 21.9% YoY to $4.3 billion, adjusted EPS rose 33.0% to $3.70, and adjusted automotive free cash flow grew 56.4% to $1.3 billion despite a sharp 77.8% decline in automotive operating cash flow to $533 million. The company raised its full-year 2026 EBIT-adjusted guidance to $13.5 billion - $15.5 billion from $13.0 billion - $15.0 billion due to a $0.5 billion favorable tariff adjustment and declared a quarterly dividend of $0.18 per share.

• ·GMNA EBIT-adjusted of $3,661 million, up 11.4% YoY.
• ·GMI EBIT-adjusted of $123 million (n.m. YoY).
• ·China equity income of $165 million (n.m. YoY).
• ·GM Financial EBT-adjusted of $688 million, up 0.5% YoY.
• ·Quarterly dividend of $0.18 per share payable June 18, 2026.
• ·Cash and cash equivalents of $19,800 million as of March 31, 2026.

28-04-2026

Kiniksa Pharmaceuticals reported Q1 2026 ARCALYST net product revenue of $214.3 million, up 56% YoY from $137.8 million, leading to total revenue of $214.3 million and net income of $22.6 million versus $8.5 million in Q1 2025. However, total operating expenses increased 49% to $185.0 million from $124.5 million, driven by rises in collaboration expenses (+73%), SG&A (+41%), R&D (+42%), and COGS (+16%). The company raised its full-year 2026 ARCALYST net product revenue guidance to $930-$945 million from $900-$920 million and maintained a cash balance of $468.1 million with expectations of remaining cash flow positive.

• ·Phase 2 dose-focusing data for KPL-387 expected in 2H 2026; Phase 3 pivotal trial initiation by end of 2026
• ·Phase 1 first-in-human trial for KPL-1161 expected by end of 2026
• ·Average total duration of ARCALYST therapy approaching 3 years

28-04-2026

Soligenix, Inc. announced interim results from the Phase 3 FLASH2 trial evaluating HyBryte™ (Synthetic Hypericin) for cutaneous T-cell lymphoma, with the Data Monitoring Committee recommending to halt the study for futility. The company stated it will evaluate strategic options, including merger and acquisition opportunities and potentially advancing dusquetide for Behçet’s Disease. No quantitative efficacy data or financial impacts were disclosed.

• ·Filing includes Exhibit 99.1: Press release dated April 28, 2026
• ·Trial targets: cutaneous T-cell lymphoma

28-04-2026

Global Interactive Technologies, Inc. entered into a Securities Purchase Agreement dated April 22, 2026, with Firstfire Global Opportunities Fund, LLC, for the exempt sale of securities under Section 4(a)(2) of the 1933 Act and Rule 506(b). The agreement includes representations confirming compliance with SEC filings, no material adverse changes since September 30, 2025, except for a Nasdaq non-compliance notice received on April 15, 2026, and no ongoing litigation or environmental issues. While the company affirms strong IP protection and tax compliance, the Nasdaq issue highlights a regulatory challenge.

• ·Nasdaq notice of non-compliance received on April 15, 2026, disclosed in Form 8-K filed April 17, 2026.
• ·Financial statements reflect position as of September 30, 2025, and year ended December 31, 2025.

28-04-2026

Semrush Holdings, Inc. filed an 8-K on April 28, 2026, including Exhibit 3.1: Second Amended and Restated Certificate of Incorporation, effective in connection with an acquisition completion (Item 2.01) and related changes (Items 3.01, 3.03, 5.01, 5.02, 5.03). The certificate authorizes 100,000 shares of a single class of Common Stock with a par value of $0.00001 per share and includes standard provisions on governance, indemnification, and director/officer liability limitations. No financial performance metrics or period-over-period comparisons are provided.

• ·Registered office: 251 Little Falls Drive, Wilmington, County of New Castle, Delaware 19808.
• ·Affirmative vote of not less than two-thirds (2/3) required to amend or repeal ARTICLE 11.

28-04-2026

Cobblestone Asset Management LLC filed a 13F-HR report disclosing $222,385,336 in equity securities across 73 holdings as of March 31, 2026. The portfolio includes positions in cryptocurrency-related assets like Coinbase Global Inc and Grayscale Solana Staking ETF, technology stocks such as Crowdstrike Holdings Inc and Palo Alto Networks Inc, and various iShares and SPDR ETFs focused on momentum, international markets, and defense sectors. No period-over-period comparisons are provided in the filing.

• ·Holdings include emerging market ETFs such as iShares MSCI Brazil ETF, iShares MSCI India ETF, and iShares MSCI South Korea ETF.
• ·Additional exposure to physical commodity trusts like Sprott Physical Gold Trust and Sprott Physical Silver Trust.

28-04-2026

NBT Bank N.A./NY filed its 13F-HR on April 28, 2026, reporting total equity holdings valued at $1,526,442,874 across 1,673 positions as of March 31, 2026. Top holdings include iShares Core S&P US (19326396 value), Vanguard Value ETF (18767119), Vanguard Total Stock Market ETF (17042882), Caterpillar Inc. (8944998), and Apple Inc. (2569939), with sole discretionary authority and no derivatives noted. The portfolio features a mix of individual stocks and ETFs, including its own parent NBT Bancorp Inc. (699222).

• ·Filing period end date: March 31, 2026
• ·All positions reported with sole voting authority (DFND 1 0 0)

28-04-2026

Ariose Capital Management Ltd filed its 13F-HR on April 28, 2026, disclosing 15 equity holdings as of March 31, 2026, with a focus on semiconductor, technology, uranium ETFs, and related sectors. Largest positions by market value include AXT Inc at $39,061,157 (685,524 shares) and Seagate Technology Holdings at $37,844,016 (96,600 shares), alongside Corning Inc at $17,231,341 (126,729 shares). All reported holdings are under sole voting authority with no shared or other voting authority indicated.

• ·Filer business address: Suite 1107, 11th Floor, ICBC Tower, 3 Garden Road, Central, Hong Kong
• ·SEC file number: 028-17188
• ·All holdings reported with sole voting authority (SH SOLE) and no other voting authority

28-04-2026

St. Johns Investment Management Company, LLC reported total holdings valued at $237,674,093 across 193 positions as of March 31, 2026, in its quarterly 13F-HR filing submitted on April 28, 2026. The portfolio is diversified with significant allocations to large-cap stocks like Apple Inc. ($12,801,836) and Microsoft Corp. ($7,549,932), as well as ETFs such as Schwab U.S. Large-Cap ETF ($26,275,378) and iShares Core S&P 500 ETF ($5,505,138). All positions are held with sole investment discretion and no shared voting authority.

• ·Filing covers period ending 03/31/2026
• ·All 193 holdings reported as sole discretion with 0 put/call options

28-04-2026

Winthrop Capital Management, LLC filed its 13F-HR on April 28, 2026, disclosing holdings as of March 31, 2026, with a total portfolio value of $389,499,000 across 357 positions held solely. The portfolio is diversified with heavy emphasis on ETFs, led by Vanguard World Fund Information Technology ETF at $32,076,000 (45,973 shares), SPDR Series Trust State Street S&P 500 ETF at $20,356,000 (676,963 shares), and Schwab U.S. Large-Cap ETF at $16,883,000 (658,461 shares). No changes from prior periods are detailed in this filing.

• ·All positions reported as SH SOLE with no put/call options or other managers.
• ·Portfolio address: 10201 N. Illinois, Carmel, IN 46290.
• ·SEC file number: 028-23672.

28-04-2026

AEW Capital Management LP filed a 13F-HR combination report disclosing $1,377,962,295 in total holdings across 78 securities as of March 31, 2026, predominantly in real estate investment trusts (REITs) managed jointly with Natixis Advisors, LLC and Russell Investments Group, Ltd. Top positions include Welltower Inc ($129.5M, 655,123 shares), Prologis Inc. ($81.0M, 612,947 shares), Simon Property Group Inc ($44.8M, 240,244 shares), Realty Income Corp ($39.1M, 639,128 shares), and VICI Properties Inc ($36.9M, 1,350,008 shares). The filing provides a current snapshot of U.S. equity positions with no period-over-period changes detailed.

• ·Holdings span REIT sub-sectors including healthcare (e.g., Welltower $129.5M), industrial (e.g., Prologis $81.0M), retail (e.g., Simon $44.8M), gaming (VICI $36.9M), and apartments (e.g., AvalonBay $58.4M).
• ·Smaller positions include Lineage Inc (550 shares, $18,018), Tanger Inc (1,862 shares, $63,271), and Stag Industrial Inc (1,552 shares, $55,965).
• ·Report filed April 28, 2026, for quarter ended March 31, 2026.

28-04-2026

Community Trust Bancorp, Inc. (CTBI) held its 2026 Annual Meeting of Shareholders on April 28, 2026, featuring a presentation by Chairman, President, and CEO Mark A. Gooch on 2025 full-year and Q1 2026 financial results, as well as future performance goals. The slides are furnished as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. No specific financial metrics are detailed in the filing itself.

• ·Presentation covers 2025 full-year and Q1 2026 (ended March 31, 2026) financial results.
• ·Filed under Items 7.01 (Regulation FD Disclosure) and 9.01 (Exhibits).

28-04-2026

Q3 Asset Management filed a 13F-HR on April 28, 2026, disclosing 64 equity holdings as of March 31, 2026, primarily consisting of ETFs and common stocks with a focus on treasuries, commodities, energy, technology, and leveraged equity products. The largest holding is Bondbloxx 6month Treasury ETF valued at $255,027,000, followed by its proprietary Q3 All Season Tactical Advantage ETF at $22,832,000 and Q3 All Season Active Rotation ETF at $17,937,000. The portfolio shows no period-over-period changes as this is a snapshot disclosure with all positions held solely.

• ·All reported holdings are held solely with zero put/call or other manager shares
• ·Filer CIK: 0001732543, SEC file number: 028-18683
• ·Business address: 2175 Cole, Birmingham, MI 48009